TAK-715

Cat. No.: 0225LY-1054

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, HPLC, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: TAK-715 acts as a targeted p38 MAPK inhibitor with specific activity against the p38α isoform.

Synonym: 303162-79-0; TAK 715; N-(4-(2-ethyl-4-(m-tolyl)thiazol-5-yl)pyridin-2-yl)benzamide; TAK715; Benzamide, N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]-; N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]pyridin-2-yl]benzamide; Benzamide, N-(4-(2-ethyl-4-(3-methylphenyl)-5-thiazolyl)-2-pyridinyl)-; compound 8h (PMID: 16162000); N-(4-(2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)pyridin-2-yl)benzamide; T75

CAS No.: 303162-79-0

Compound CID: 9952773

Formula: C₂₄H₂₁N₃OS

Formula Weight: 399.51

Specification

Targets&IC50: p38β: 0.20 μM; p38α: 7.1 nM

Relative Density: 1.233 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: TAK-715 can be used in autoimmune research to investigate the selective inhibition of p38 alpha MAPK and its effect on cytokine release.